Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 8/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 6/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315135 | 1.00 | BIRC2 (0.42) | BIRC2HRH4JAK3TP53MDM2 | |
| SCHEMBL21543186 | 1.00 | BIRC2 (0.42) | BIRC2HRH4JAK3TP53MDM2 | |
| Trifluoroacetic Acid SCHEMBL20296401 | 0.89 | BIRC2 (0.36) | BIRC2HRH4JAK3BTK | |
| Trifluoroacetic Acid SCHEMBL20296403 | 0.89 | BIRC2 (0.36) | BIRC2HRH4JAK3BTK | |
| SCHEMBL24504943 | 0.81 | REN (0.37) | JAK3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22972524 | 0.81 | REN (0.37) | JAK3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24474102 | 0.80 | BIRC2 (0.41) | BIRC2HRH4JAK3TP53MDM2 | |
| SCHEMBL26774293 | 0.79 | BIRC2 (0.37) | BIRC2HRH4TP53MDM2 | |
| SCHEMBL30586695 | 0.79 | MAPT (0.44) | — | |
| SCHEMBL17582672 | 0.79 | KRAS (0.32) | JAK3BTKJAK1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182470-A1 | KRASG12C MUTANT PROTEIN INHIBITOR, PREARATION AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-06 | — | — | US | disclosed |
| CN-115490689-B | Irreversible KRAS G12C Preparation and application of inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115160309-B | KRAS G12C Preparation and application of mutant protein heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115304603-B | Preparation and application of quinazoline inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3842433-B1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-115490689-A | Irreversible KRAS G12C Preparation of inhibitors and uses thereof | 药雅科技(上海)有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115304603-A | Preparation and application of quinazoline inhibitor | 药雅科技(上海)有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115160309-A | KRAS G12C Preparation and application of mutant protein heterocyclic inhibitor | 药雅科技(上海)有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022193982-A1 | PREPARATION AND USE OF KRASG12C MUTEIN INHIBITOR | 药雅科技(上海)有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-115073450-A | KRAS G12C Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073451-A | KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3842433-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182470-A1 | KRASG12C MUTANT PROTEIN INHIBITOR, PREARATION AND USE THEREOF | KRAS, NRAS, HRAS | BIRC2 712/4885HRH4 4062/4885JAK3 1218/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | BIRC2 145/4885HRH4 2663/4885JAK3 3267/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | BIRC2 414/4885HRH4 3402/4885JAK3 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.